Healthcare Deal Structures: Rollover Equity, Earnouts and MSOs in 2026
A private equity offer for a healthcare practice pays in up to three forms: cash at close, rollover equity in the buyer's platform and an earnout paid later if targets are hit. A management services organization (MSO) then runs the non-clinical business and charges a fee that decides who keeps the economics.
Compare offers on the cash you actually receive on day one, after escrow and the working capital adjustment. Then price the rollover and earnout as scenarios, not at face value. Four terms move the most money: the rollover waterfall, the earnout metric definition, the compensation reset and the management fee. This guide works through each with 2025 deal data and seven worked examples.
Page updated November 20, 2026. Each figure names its source, population and period. Every worked example is our arithmetic on the stated assumptions.
2025 Healthcare PE Deal Data Behind These Structures
| Measure | Figure | Population, period and source |
|---|---|---|
| Healthcare PE deal value | Estimated $191 billion, above the 2021 peak | Global, 2025 estimate. Bain & Company, Global Healthcare PE Report 2026 press release |
| Healthcare PE buyouts announced | 445, the second most on record | Global, 2025 estimate. Bain press release |
| Healthcare PE exit value | Expected $156 billion, up from $54 billion in 2024 | Global, 2025 estimate. Bain press release |
| Sponsor-to-sponsor deals | More than 150 expected and more than $120 billion in estimated value, both records | Global, 2025 estimate. Bain press release |
| Large North American deals | 26 above $1 billion, against 14 in all of 2024. More than 70% were sponsor-to-sponsor | North America, as of November 2025. Bain press release |
| North America's share of provider deal value | More than 60% of global provider deal value | Global provider deals. Bain, New Models of Value Creation for Physician Groups, 2026 report. Its 2025 figures are actual data through November 30, 2025, annualized for the rest of the year |
| PE-backed healthcare deals tracked | 1,029: 151 buyouts, 664 add-ons and 214 growth investments, across 420 platforms and 708 investment firms | U.S. PE-backed healthcare deals, 2025. Private Equity Stakeholder Project (PESP), 2025 in Review, using PitchBook and LevinPro HC data. PESP calls the count likely an underestimate |
| Busiest subsectors by PE deal count | Health IT 151, dental 149, outpatient 148, medtech 117, behavioral health 56 | Same PESP population, 2025. PESP |
| Dental PE deals that were add-ons | 95% of 149 | Same PESP population, 2025. PESP |
| Top outpatient subsectors by deal count | Dermatology 24, eye care 22, oncology 9 | PESP 2025 outpatient data reported by Becker's ASC Review |
| Physicians in PE-owned practices | 6.5%, against about 4.5% in both 2020 and 2022 | U.S. physicians, 2024 survey. AMA, Physician Practice Characteristics in 2024 |
| Physician and clinical services spending | $1,109.7 billion in 2024, up 8.1%. Projected to grow 5.5% a year on average from 2025 through 2034 | U.S. national health expenditure. CMS NHE fact sheet |
Bain and PESP count different populations, so do not add or compare their totals. Bain reports global healthcare private equity using its own deal criteria, and its 2025 figures are estimates, some based on data through November and annualized for the rest of the year. PESP counts PE-backed deals it finds in PitchBook and LevinPro HC, small add-ons included.
PESP's split is the one that matters to a practice owner. Add-ons were 664 of the 1,029 deals it tracked, and 95% of dental deals were add-ons to PE-owned platforms. Most sellers join a platform that already has its holding company, lenders and management services agreement in place. Your bargaining power sits in the terms you negotiate inside that structure.
The CMS figures explain why buyers keep paying for practices. A spending category of more than $1.1 trillion, projected to grow 5.5% a year through 2034, is the growth story a platform sells at exit, and the one your rollover depends on.
The AMA survey shows how recent this ownership is. In 2024, 38% of physicians in PE-owned practices said their practice had been acquired in the past five years, and 17.1% said it had been acquired before 2015. Among physicians in hospital-owned practices, 47.2% said their practice had been acquired before 2015.
Match the Structure to Your Goal
| Your priority | Structure to push for | What you give up |
|---|---|---|
| Certainty and cash now | Higher cash share at close, smaller rollover, no earnout | Headline price and upside in the platform's next sale |
| A second payday at a higher valuation | Meaningful rollover on the same terms as sponsor equity | Access to that money for years, plus exposure to platform debt and execution |
| Bridging a disagreement on forecast | Earnout on a metric you can influence and audit | Control over the result once the MSO runs operations |
| Higher personal income after closing | A smaller compensation reset | Headline price, at the buyer's multiple |
| Steady income independent of the exit | Keep the real estate and lease it to the buyer | Cash from the building today |
| Keeping a service line or location | Carve it out into a separate entity | A lower price on the rest of the practice |
| More equity with less dilution | Royalty or structured capital from an investor | A slice of revenue every year, ahead of your profit |
| A long-term partner with no forced sale | Minority investment from a family office with a defined path to cash | The sponsor exit premium that a PE rollover targets |
Compare Two Offers by Cash at Close
A private equity or MSO-backed offer for a physician practice has four parts:
- Cash at close: what lands in your account on day one, before escrow and adjustments.
- Rollover equity: value you reinvest in the buyer's platform, usually as a minority holder in a holding company above the MSO.
- Earnout: money paid later if targets are hit.
- Management services agreement: moves non-clinical operations, and much of the economics, to the MSO.
Investors split the MSO from the professional corporation (PC) because of limits on who can own a medical practice. Ask your own attorney how those limits apply in your state. See our explainer on management services organizations.
Size buys cash. FOCUS Investment Banking's Dermatology Practice Valuation: 2026 Benchmarks reports that platform-ready dermatology practices, typically targeting $5 million or more in EBITDA, get the highest valuations and the most favorable structures, often 70% or more cash at close with meaningful rollover. The same report counts more than 35 sponsor-backed dermatology platforms operating nationally in 2026. Smaller add-ons usually carry a larger share in rollover and deferred pay.
Worked example 1: two offers (our arithmetic). Assumptions: the headline price counts rollover at issue value and the full earnout. Payouts are undiscounted, pre-tax and before escrow or working capital adjustments.
| Offer A | Offer B | |
|---|---|---|
| Headline price | $12.0 million | $10.0 million |
| Cash at close | 60% = $7.2 million | 80% = $8.0 million |
| Rollover equity | 25% = $3.0 million | 20% = $2.0 million |
| Earnout | 15% = $1.8 million | None |
| Total at risk | $4.8 million | $2.0 million |
Offer B pays $0.8 million more on day one. Offer A wins only if its rollover and earnout together return more than $0.8 million above what Offer B's rollover returns.
| Scenario | Offer A total | Offer B total | Result |
|---|---|---|---|
| Earnout pays half ($0.9 million), both rollovers return face value | $11.1 million | $10.0 million | A wins by $1.1 million |
| Earnout pays nothing, both rollovers return half of face | $8.7 million | $9.0 million | B wins by $0.3 million |
The $2 million headline gap is a trade. You give up $0.8 million of certainty for a chance at more, and that chance depends on a platform exit you do not control. Run every term sheet through the Deal Proceeds Calculator. Enter rollover at cost, because you cannot sell it until the platform does, and enter earnout outcomes as scenarios, not forecasts. For how platforms are built, see private equity physician roll-ups.
Rollover Equity: Exit Waterfalls and Unit Terms
You contribute part of your practice interests, or reinvest part of your proceeds, in the platform's holding company in exchange for units. Those units are worth what the platform fetches when the sponsor sells or recapitalizes.
The case for rollover is a second sale at a higher valuation once the platform has scaled. That exit market was active in 2025. Bain estimates more than $120 billion in global sponsor-to-sponsor deal value for the year, and more than 70% of the 26 North American healthcare PE deals above $1 billion through November 2025 were sponsor-to-sponsor sales. Bain also reports that physician groups remain a major part of PE portfolios despite the decline in deal volumes from their peak. Strategic buyers take out platforms too. Bain's physician group analysis cites strategic deals such as Cardinal Health's acquisition of a majority stake in urology platform Solaris Health and Cencora's purchase of a controlling stake in Retina Consultants of America.
No public dataset tracks what rollover holders receive per unit, because the second sale happens at the platform level. Get it from the sponsor. Ask for its record on prior exits and recapitalizations, the dollars per unit rollover holders received in each, the holding period and the growth plan the next sale depends on. Then speak with physicians who rolled into an earlier platform from the same fund. SEC EDGAR full-text search is a free cross-check, because private offering notices filed there show when a sponsor's funds and platforms raised private capital.
What your units pay at three exit values
Debt and preferred equity sit ahead of common units. The same rollover can return a fraction of cost or a multiple of it, and the preferred terms decide which.
Worked example 2: rollover payout (our arithmetic). Assumptions: the platform is bought at a $300 million enterprise value with $150 million of debt, so entry equity is $150 million. You roll $3.0 million, which is 2% of entry equity on an as-converted basis. Debt is still $150 million at exit. Fees, taxes, management incentive pools and accrued preferred dividends are ignored. In the two preferred columns, $50 million of entry equity is a 1x preferred held by the sponsor. The other $100 million, including your $3.0 million, is common, so you hold 3% of the common class.
- Non-participating preferred: the sponsor takes the greater of its $50 million back or its as-converted one-third share of total equity after debt, measured before any preference is paid.
- Participating preferred: the sponsor takes $50 million first and then shares in the rest as if converted.
| Exit enterprise value | Equity after debt | Single common class | 1x non-participating preferred | 1x participating preferred |
|---|---|---|---|---|
| $250 million (below entry) | $100 million | $2.0 million | $1.5 million | $1.0 million |
| $300 million (at entry) | $150 million | $3.0 million | $3.0 million | $2.0 million |
| $600 million (twice entry) | $450 million | $9.0 million | $9.0 million | $8.0 million |
How the rows work. At $250 million, the non-participating sponsor keeps its $50 million preference because converting would pay only $33.3 million, so you get 3% of the remaining $50 million. At $600 million the sponsor converts, because one-third of $450 million is $150 million, and you get 2% of the full $450 million. The participating preferred takes $50 million in every row and you get 2% of what is left.
Debt magnifies both directions. A one-sixth fall in enterprise value, from $300 million to $250 million, cuts equity by a third. A doubling triples it. A participating preference costs you money even at the entry price, and accrued preferred dividends lower the common payout further in every row. Make the buyer produce this table with the actual capital structure and waterfall before you sign.
Four terms that set the value of the stake
| Term | Question to ask | Common seller ask |
|---|---|---|
| Issue price and date | Is the unit price fixed at signing or at closing? Does it match what new cash investors pay? | Price at closing, or an agreed adjustment formula, on the same terms as new cash |
| Class and preferences | Do rollover units rank below preferred equity? Is the preferred participating? Does it accrue a dividend? | Same class as sponsor common, or a written waterfall with non-participating preferred |
| Minority protections | What information rights, consent rights and anti-dilution limits apply? | Consent over related-party deals and changes to your class |
| Drag, tag and call rights | When does your second payday come, at what price, and can the sponsor buy you out early? | Tag-along on any sponsor sale, calls at fair value except for misconduct |
Call rights are where rollover holders get hurt. Many agreements let the sponsor buy back units at cost, or at a discount, after a defined bad act. That definition sets the floor on your stake. Limit it to fraud and misconduct, not resignation, a missed production target or a dispute with management.
A seller who keeps equity usually also signs an employment agreement with the platform. Find out whether resignation, termination without cause or non-renewal of that agreement triggers a call, and ask for fair value for anything short of misconduct. The Rollover Equity Calculator runs the exit cases, and the Physician Rollover Equity Checklist covers the documents.
Earnouts: 2025 Frequency, Payout Rates and Metric Traps
SRS Acquiom's 2026 M&A Earnout and Milestone Trends covers private-target deals in its own transaction dataset. Across all 2025 deals outside life sciences, 24% included an earnout. Each row below is a separate cut of that dataset, and the rows overlap.
| SRS Acquiom segment | 2025 deals with an earnout | 2014 to 2022 |
|---|---|---|
| Biotech and pharma targets (earnouts or milestones) | 78% | 72% |
| Healthcare services targets | 37% | 26% |
| Lower middle market ($50 million or less) | 30% | 23% |
| U.S. private equity buyers | 24% | 13% |
| Tech targets | 22% | 14% |
| U.S. public buyers | 18% | 15% |
| Jumbo deals (more than $750 million) | 6% | 5% |
SRS does not report physician practice sales as a segment. A practice sale to a PE-backed platform would usually resemble three of these segments, healthcare services target, PE buyer and lower middle market, but SRS does not classify individual deals that way or report the combination. Each of those three rows sits at or above the 24% overall rate.
Partial success pays partially. SRS reports that in deals with upfront payments above $50 million, earnouts that achieved any level of success paid 67 cents on the dollar. That figure covers larger deals only, and the report gives no matching figure for smaller ones.
Worked example 3: how the metric definition moves the payout (our arithmetic)
Assumptions: the earnout pays $1.8 million if first-year EBITDA reaches $2.0 million, nothing at $1.6 million or below, and a straight-line share in between. Under the seller's definition, the practice earns $2.05 million. After closing, the platform allocates $200,000 of corporate overhead to the practice.
| Seller's definition | After overhead allocation | |
|---|---|---|
| Measured EBITDA | $2.05 million | $1.85 million |
| Share of earnout earned | 100% | ($1.85M - $1.6M) รท $0.4M = 62.5% |
| Payout | $1.8 million | $1.125 million |
One accounting choice by the buyer cost the seller $675,000. The practice performed no worse.
Five terms that shift earnout risk to the seller
- EBITDA metric without definitions. The buyer sets cost allocations, management fees and integration charges after closing. Revenue or collections are harder to move. If EBITDA is the metric, list the add-backs and fix the corporate charges in the agreement.
- Window that starts at signing. Regulatory review and financing can push closing out by months. Every month before closing is a month you are measured without the buyer's resources.
- No operating covenants. Without written commitments to keep your location open, staffed and marketed, the buyer's own decisions can sink your target. Exclude the cost of any conditions a regulator attaches to approval.
- All-or-nothing targets. A cliff at one number turns a near miss into zero. Ask for straight-line payment between a floor and a target, and a catch-up if a missed year is made up later.
- No audit, offset or acceleration terms. Agree who calculates the payout, how you audit it, whether the buyer can offset indemnity claims against it and whether it accelerates if the platform is sold during the window.
The larger the deferred share the buyer controls, the more security to ask for: a higher cash share, collateral such as receivables or equipment, or a guarantee behind the deferred amount. Price the earnout with the Earnout Value Calculator and screen the rest of the term sheet with our LOI and term sheet red flags.
Worked example 4: what delay does to a signing-date window (our arithmetic)
Assumptions: a 12-month earnout window starts at signing. Closing comes 3, 6 or 9 months later. The delays are illustrations, not predictions of any review.
| Months from signing to closing | Months of the window under buyer ownership | Window anchored to closing |
|---|---|---|
| 3 | 9 | Full 12 months |
| 6 | 6 | Full 12 months |
| 9 | 3 | Full 12 months |
At six months, half the window measures a practice the buyer does not yet run, and rollover units priced at signing are six months stale by closing. The seller's position is to price units at closing or by an agreed formula, anchor the earnout to closing or extend it for delay, and set an outside date long enough to cover the slowest review.
Escrow, Indemnity, Working Capital and Compensation Resets
The headline price is gross. These terms in the purchase agreement and employment agreement decide how much of it you keep.
| Term | How it moves your money | Seller position |
|---|---|---|
| Indemnity escrow or holdback | Part of cash at close is held back for a set period to pay buyer claims for breaches of your representations | Size and term tied to risks found in diligence, release in stages, escrow as the buyer's only recourse for general representation breaches |
| Basket and cap | The basket is the loss the buyer absorbs before it can claim. The cap is the most it can recover | A deductible basket rather than a first-dollar one, and a cap equal to the escrow for general representations |
| Representations and warranties insurance (RWI) | A buyer-side policy pays covered breach claims, so less of your cash sits in escrow | Ask whether the buyer will bind a policy, who pays the premium and how far the seller escrow shrinks. Issues known before signing are excluded and usually move to a special indemnity you fund |
| Working capital peg | The price assumes a normal level of working capital at closing. A shortfall cuts the price dollar for dollar | A peg built from a trailing average that reflects seasonality, with receivables valued at what your payer mix actually collects |
| Compensation reset | Post-close physician pay is set below what the owners drew. The difference becomes EBITDA the buyer pays a multiple on | Model the reset against the price it creates and the years you will work under it |
| Non-compete and non-solicit | Limits where and how you practice after closing or after you leave | A radius matched to your real service area, a term tied to the sale rather than restarted by each employment renewal, and a release if you are terminated without cause |
Worked example 5: from headline price to cash in hand (our arithmetic)
Assumptions: a $10.0 million headline price with 70% cash at close. The buyer holds 10% of the headline price in escrow for 18 months, funded from the cash at close. The working capital peg is $1.2 million and the practice delivers $0.95 million at closing. One $300,000 indemnity claim is paid from escrow. These inputs are illustrations, not market norms.
| Step | Amount |
|---|---|
| Cash at close on the term sheet | $7.0 million |
| Less escrow held back (10% of $10.0 million) | $1.0 million |
| Less working capital shortfall ($1.2M peg - $0.95M delivered) | $0.25 million |
| Cash received at closing | $5.75 million |
| Escrow released after the $300,000 claim | $0.7 million |
| Total cash from the cash-at-close portion | $6.45 million |
The term sheet said $7.0 million. The seller received $6.45 million, 92% of it, and waited 18 months for $0.7 million of that.
Worked example 6: the compensation reset trade (our arithmetic)
Assumptions: three physician owners each draw $1.0 million, which is all of the practice's $3.0 million of profit before owner pay. The buyer resets pay to $700,000 each, or $2.1 million in total, leaving $0.9 million of EBITDA. The buyer pays an illustrative 8x multiple. Employment agreements run five years. All figures are pre-tax.
| Total | Per physician | |
|---|---|---|
| EBITDA created by the reset | $0.9 million | $0.3 million |
| Headline price at 8x | $7.2 million | $2.4 million |
| Cash at close if 60% of price | $4.32 million | $1.44 million |
| Annual pay given up | $0.9 million | $0.3 million |
| Pay given up over five years | $4.5 million | $1.5 million |
On headline price the reset looks like a win: $2.4 million per physician against $1.5 million of pay given up. On certain cash it is not. At 60% cash at close, each physician banks $1.44 million on day one and gives up $1.5 million in pay. The rest of the price rides on rollover and earnout.
At the margin, each extra $100,000 of pay cut per physician adds $300,000 of practice EBITDA and $2.4 million of headline price, or $800,000 per physician. Over five years each physician gives up $500,000 of pay for it, against $480,000 of cash at close at a 60% cash share. Model the reset with the employment term, the cash share and the tax difference between sale proceeds and wages side by side.
How rollover and earnout payments are taxed
| Item | What drives the treatment | Question to settle before the LOI |
|---|---|---|
| Rollover equity | Whether tax on the rolled portion is due at closing or deferred depends on how the deal is structured and on your own circumstances. Ask your own tax adviser and attorney | If the rollover is taxed at closing, the tax on the rolled portion comes out of your cash at close. Who models that? |
| Earnout | How later payments are taxed depends on how they are structured, including whether they are tied to your continued employment. Ask your own tax adviser and attorney | Is any payment conditioned on your tenure rather than the practice's results? |
| Seller note | The timing of tax on note payments and the treatment of interest depend on how the sale is reported. Ask your own tax adviser | Does the note's security match the tax you will owe as it pays? |
The MSO and PC Split: Who Holds What
The table shows a common allocation in MSO and PC deals. These are patterns, not rules. The deal documents decide the final split.
| Item | Physician-owned PC | Investor-backed MSO | Where deals differ |
|---|---|---|---|
| Ownership | Licensed physician owner(s) | Sponsor, rollover holders and other investors | Who may own the PC |
| Clinical decisions | Diagnosis, treatment, clinical protocols | No clinical control | How far "non-clinical" support reaches |
| Licenses and registrations | Professional licenses, practice entity registrations | Business licenses for its own services | Licensing requirements |
| Payer contracts | Often the contracting provider | Billing, collections and contracting support as a vendor | Some deals contract differently |
| Staff | Physicians and clinical staff | Front office, revenue cycle, HR, IT, finance | Who employs clinical staff |
| Economics | Professional fees, less the management fee | Management fee and the platform's equity value | Fee method and size |
| Control documents | Signs the services agreement | Often holds transfer restrictions on PC ownership | Scope of restrictions |
The management fee is the most important economic term in the structure. It decides how much of each dollar of collections stays with the PC and its physicians and how much flows to platform equity. Get in writing the fee method (fixed, cost-plus or percentage), the services it covers, how it can change and how it interacts with your earnout metric. A fee increase during the earnout window lowers measured EBITDA the same way the overhead allocation does in worked example 3.
Some states require notice or review of healthcare transactions, including deals involving PE-backed MSOs, and that review can affect both deal structure and the closing date that worked example 4 depends on. Raise it with your own attorney early. Draft the services agreement, transfer restriction agreement and physician employment contracts in parallel with any review so the paperwork does not add delay. Our healthcare M&A process guide covers the sequence.
Real Estate, Carve-Outs, Royalties and Seller Notes
Real estate. Owners who hold the building under their practice can keep it and lease it to the buyer. Rent does not depend on the platform's exit or an earnout formula. Set rent at fair market value and support it with an independent appraisal, because the lease is part of the same deal and gets the same scrutiny.
Carve-outs. A service line, device program or location you want to keep can sit in a separate entity outside the sale. That gives you a partial exit now and options later. The buyer will cut the price for the carve-out, so decide early whether the piece is worth the discount.
Royalties. An investor's royalty on revenue is the price of keeping more equity. Size it against operating income, not collections.
Worked example 7: royalty burden (our arithmetic). Assumptions: $5.0 million in collections and $4.0 million of operating costs, including market-rate physician pay, so operating income is $1.0 million.
| Royalty rate on collections | Annual payment | Share of operating income |
|---|---|---|
| 3% | $150,000 | 15% |
| 8% | $400,000 | 40% |
A rate that looks small on revenue can take close to half the profit. If collections fall 5% to $4.75 million and costs stay at $4.0 million, operating income falls 25% to $750,000. The 8% royalty drops only to $380,000 and now takes about 51% of operating income.
Seller notes. A seller note plus rollover means a large share of your price is neither cash nor sellable. Value the note at face only if it is secured. Fix the rate, term, collateral, ranking behind platform lenders and acceleration on default or a platform sale. Notes also show up when the buyer is another physician rather than a platform. A physician buyer financing through the SBA 7(a) program faces the program's loan size limits, so check the current limit on the SBA page. On a larger practice, part of the gap above what the buyer can borrow and contribute may be filled by a note from you. See healthcare debt financing for how lenders rank.
Who Models Each Term Before You Sign the LOI
Most of the money in these structures moves on terms that are modeled late or not at all. Assign each workstream before the letter of intent, and hand each adviser the matching worked example so the output comes back in dollars. Check the registration and disclosure history of any banker or firm you hire on FINRA BrokerCheck.
| Workstream | Who usually leads | Start from | Output you need before the LOI |
|---|---|---|---|
| Net proceeds by offer | Financial adviser or banker | Worked examples 1 and 5 | Day-one cash, cash at risk and scenario totals for every offer on the table |
| Quality of earnings | Sell-side accountant | Owner pay history, add-backs, monthly working capital | Defended EBITDA and your own working capital peg proposal |
| Rollover waterfall | Financial adviser, using the sponsor's capital table | Worked example 2 | Your payout at three exit values under the actual preferred terms |
| Earnout definition | Accountant | Worked examples 3 and 4 | Written metric, listed add-backs, fixed corporate charges and a window anchored to closing |
| Compensation reset | Financial adviser and tax adviser | Worked example 6 | Pay given up over the employment term against cash at close created, after tax |
| Tax structure | Tax adviser | The tax table above | Modeled tax on the rolled portion, the earnout and any seller note |
| Fees, leases and royalties | Financial adviser | Worked example 7 and the management fee terms | Fee method, rent appraisal and royalty burden at a 5% revenue decline |
Two rules keep this efficient. First, ask the buyer for its waterfall, management fee schedule and overhead allocation policy early, because three of the seven rows depend on them. Second, rerun the net proceeds row after every round of term sheet changes, since escrow, peg and reset changes rarely show up in the headline price.
Push, Trade or Accept: Pricing Each Term Against the Worked Examples
Every term on a healthcare term sheet has a dollar cost, and the worked examples above put a number on most of them. Use this table to decide where to spend negotiating capital. Push hardest where the dollars at stake are largest relative to your day-one cash, and trade on terms where the buyer's cost is lower than your gain.
| Term | Dollars at stake on this page | Push for | Trade it for | Accept when |
|---|---|---|---|---|
| Cash share at close | $0.8 million more day-one cash in Offer B (example 1) | A higher cash share if the money at risk is more than you can afford to lose | A larger rollover only if your downside scenario still beats the cash gap | The sponsor's record on prior exits supports your upside scenario |
| Rollover preferred terms | $1.0 million lost at the entry price under a participating preferred ($2.0 million back on $3.0 million rolled, example 2) | One common class, or a non-participating preferred | A smaller rollover on common terms | Your payout at twice entry ($8.0 million on $3.0 million) still justifies the lockup |
| Earnout metric | $675,000 lost to one overhead allocation (example 3) | Revenue or collections, or EBITDA with listed add-backs and fixed corporate charges | A lower target amount in exchange for a metric you control | The definitions are written and you hold an audit right |
| Earnout window | Half the window lost at a six-month closing delay (example 4) | A window anchored to closing | A month-for-month extension for any delay | Signing and closing are expected close together |
| Escrow and working capital peg | $0.55 million between term sheet cash and cash received, 92% delivered (example 5) | A trailing-average peg and staged escrow release | A larger escrow in exchange for RWI or a faster release | The peg reflects seasonality and your actual collections |
| Compensation reset | $1.5 million of pay given up against $1.44 million of cash at close per physician (example 6) | A smaller reset if you plan to work the full term | A deeper reset only for a higher cash share | Your planned years of practice are shorter than the employment term |
| Royalty | 40% of operating income at 8%, rising to about 51% after a 5% revenue drop (example 7) | A rate sized to operating income, with a cap | A lower rate in exchange for a shorter term | The rate stays near 3% of collections, or about 15% of operating income |
| Management fee | Same mechanics as the overhead allocation in example 3 | A fixed method that cannot change during the earnout window | A fee increase only with a matching earnout target adjustment | The fee schedule is written and excluded from the earnout metric |
Three signals should pause a deal rather than prompt another counteroffer: a buyer that will not produce its waterfall at three exit values, a management fee that can change at the buyer's discretion during the earnout window, and an overhead allocation policy that is not written down before signing. Earnouts, management fees, leases, royalties and rollover units that involve physicians who refer patients raise referral and ownership questions, so take those to your own attorney using our healthcare compliance due diligence guide as the starting point.
Pre-LOI Checklist for Practice Owners
- [ ] Cash at close. What share of the headline price is paid at closing, and what share is rollover, earnout or note?
- [ ] Net cash. After escrow and the working capital adjustment, what lands in your account on day one?
- [ ] Escrow and indemnity. What is the escrow size and term, the basket type and the cap? Will the buyer bind RWI?
- [ ] Working capital peg. How was it set, and how are receivables valued?
- [ ] Compensation reset. What is post-close pay, for how many years, and what cash at close does the reset create at the buyer's multiple?
- [ ] Earnout start and metric. Does the window start at closing or extend for delay? Are overhead allocations, fee changes and regulator-imposed costs excluded?
- [ ] Rollover pricing and waterfall. Are your units priced at closing on new-investor terms? Is the preferred participating? What do you get at three exit values?
- [ ] Calls and non-competes. What triggers a call at cost, and what restrictions apply if you leave?
- [ ] Sponsor record. What did rollover holders in the sponsor's prior platforms receive per unit, and after how long?
- [ ] Management fee. How is it calculated, and how can it change during the earnout window?
- [ ] Seller note terms. What secures the note, and where does it rank against platform debt?
- [ ] Closing path. Which review sets the closing date, and what happens to price and terms if it runs long?
For the sale process itself, see selling a physician practice.
Questions Practice Owners and Investors Ask
Can I keep my real estate when I sell my practice?
Yes. Many sellers hold the building in a separate entity and lease it to the buyer at closing. The property then pays rent that does not depend on the platform's exit. Negotiate the lease alongside the purchase agreement and set the term, renewal options, rent escalators and who pays for capital repairs. Support the rent with an independent fair market value appraisal. If you later want cash from the building, you can sell it to a real estate investor subject to the lease. A long lease to a creditworthy platform supports that sale price.
What is a quality of earnings report and why does it change the structure?
A quality of earnings (QoE) report is an accounting review of the practice's EBITDA. The buyer normally commissions one, and some sellers commission their own first. It sets the EBITDA the buyer pays a multiple on, the baseline any earnout is measured against and the working capital peg. Every adjustment it removes comes off the price at the multiple. A sell-side QoE done before you go to market lets you defend add-backs and owner compensation adjustments before a buyer uses them to cut the price.
What happens to my earnout and rollover if the platform is sold during the earnout window?
The drafting decides it, so settle it before signing. On the earnout, ask for acceleration at the target amount, or at a pro rata amount, if the platform is sold or your practice is merged into another unit before the window ends. On the rollover, a tag-along right lets you sell your units on the same terms as the sponsor, and the waterfall decides what those units pay. Without both terms, a platform sale can cut off the earnout and leave your units with a new owner you did not pick.
How do family offices structure healthcare deals differently from private equity funds?
A family office invests its own capital and is not bound by a fund's fixed life, so it can hold longer, take minority positions and use less debt. That changes the rollover logic. A private equity rollover pays when the sponsor sells. A family office stake may have no planned sale, so the seller needs another path to cash, such as a regular distribution policy, a put right at a formula price after a set number of years, or a right to sell to the family office on agreed terms.
Sources
- Centers for Medicare & Medicaid Services, National Health Expenditure Fact Sheet
- SRS Acquiom, 2026 M&A Earnout and Milestone Trends
- Bain & Company, Global Healthcare Private Equity Report 2026, press release
- Bain & Company, New Models of Value Creation for Physician Groups, Global Healthcare Private Equity Report 2026
- Private Equity Stakeholder Project, Private Equity Healthcare Deals: 2025 in Review (PitchBook and LevinPro HC data)
- Becker's ASC Review, The outpatient specialties that dominated 2025 deal activity (PESP data)
- American Medical Association, Physician Practice Characteristics in 2024
- FOCUS Investment Banking, Dermatology Practice Valuation: 2026 Benchmarks
- U.S. Small Business Administration, 7(a) loans
- SEC EDGAR full-text search
- FINRA BrokerCheck